DISEASE BURDEN OF DIABETIC KIDNEY DISEASE IN CHINA: A SYSTEMATIC LITERATURE REVIEW
Author(s)
Wenbin Tang, PhD, MD1, Liang Tan, MD2, Yang Luo, MD1, Ting Zhang, MD1, Fang Liu, PhD, MD1, Li Yan, MD2, Wendong Chen, PhD, MD1;
1Xiangya Hospital, Central South University, Changsha, China, 2Changsha Normin Health Technology Ltd, Changsha, China
1Xiangya Hospital, Central South University, Changsha, China, 2Changsha Normin Health Technology Ltd, Changsha, China
OBJECTIVES: To systematically summarize the disease burden among patients with diabetic kidney disease (DKD) in China.
METHODS: A systematic literature review was conducted to identify published observational studies involving Chinese patients with DKD from January 2019 to March 2024 through searches of six major English and Chinese databases. Data on clinical characteristics, metabolic control, disease progression, and economic burden were extracted and synthesized using single-arm meta-analysis with a random-effects model.
RESULTS: 267 studies were included for the evidence synthesis. The pooled mean age was 58.2 years and 58.8% were male. A substantial proportion of patients had early-stage chronic kidney disease (CKD) (stage I: 31.7%; stage II: 20.9%). Hypertension (65.0%) and dyslipidemia (50.2%) were the most common comorbidities, while neuropathy (50.8%) and retinopathy (47.8%) were frequent diabetes-related complications. Metabolic control was suboptimal, with a mean hemoglobin A1c (HbA1c) level of 8.4%, and a low-density lipoprotein cholesterol (LDL-C) level of 2.8 mmol/L; only 23.1% achieved glycemic targets. Prognosis worsened with advancing CKD stage: the annual incidence of end-stage renal disease (ESRD) reached 62.8% among patients with CKD stages III-IV and annual mortality peaked at 40.9% in patients receiving dialysis. Direct annual medical costs increased with disease severity, rising from ¥1,362 in CKD stages I-II to ¥11,765 in CKD stage V.
CONCLUSIONS: Patients with DKD in China face a substantial disease burden, characterized by a high prevalence of comorbidities and diabetes-related complications, suboptimal metabolic control, progressive renal deterioration, and increasing healthcare costs with advancing disease severity.
METHODS: A systematic literature review was conducted to identify published observational studies involving Chinese patients with DKD from January 2019 to March 2024 through searches of six major English and Chinese databases. Data on clinical characteristics, metabolic control, disease progression, and economic burden were extracted and synthesized using single-arm meta-analysis with a random-effects model.
RESULTS: 267 studies were included for the evidence synthesis. The pooled mean age was 58.2 years and 58.8% were male. A substantial proportion of patients had early-stage chronic kidney disease (CKD) (stage I: 31.7%; stage II: 20.9%). Hypertension (65.0%) and dyslipidemia (50.2%) were the most common comorbidities, while neuropathy (50.8%) and retinopathy (47.8%) were frequent diabetes-related complications. Metabolic control was suboptimal, with a mean hemoglobin A1c (HbA1c) level of 8.4%, and a low-density lipoprotein cholesterol (LDL-C) level of 2.8 mmol/L; only 23.1% achieved glycemic targets. Prognosis worsened with advancing CKD stage: the annual incidence of end-stage renal disease (ESRD) reached 62.8% among patients with CKD stages III-IV and annual mortality peaked at 40.9% in patients receiving dialysis. Direct annual medical costs increased with disease severity, rising from ¥1,362 in CKD stages I-II to ¥11,765 in CKD stage V.
CONCLUSIONS: Patients with DKD in China face a substantial disease burden, characterized by a high prevalence of comorbidities and diabetes-related complications, suboptimal metabolic control, progressive renal deterioration, and increasing healthcare costs with advancing disease severity.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EPH173
Topic
Epidemiology & Public Health
Disease
SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity), SDC: Urinary/Kidney Disorders